- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03732898
Coordinated Reset Deep Brain Stimulation (RESET-DBS)
June 11, 2024 updated by: Boston Scientific Corporation
Coordinated Reset Deep Brain Stimulation (RESET-DBS)
The study will explore the viability of an alternative programming strategy in Deep Brain Stimulation (DBS) for patients with Parkinson's Disease (PD).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The study will explore the feasibility of utilizing an alternative programming technique in Deep Brain Stimulation (DBS) for patients with Parkinson's Disease (PD).
Study Type
Interventional
Enrollment (Estimated)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Cleo Mertz
- Phone Number: 855-213-9890
- Email: BSNClinicalTrials@bsci.com
Study Contact Backup
- Name: Diane Keesey
- Phone Number: 855-213-9890
- Email: BSNClinicalTrials@bsci.com
Study Locations
-
-
-
Berlin, Germany
- Recruiting
- University Berlin, Charite Virchow
-
Contact:
- Boston Scientific Clinical Research Manager
- Phone Number: 855-213-9890
- Email: BSNClinicalTrials@bsci.com
-
Wuerzburg, Germany
- Recruiting
- Universitaetsklinikum Wuerzburg
-
Contact:
- Boston Scientific Clinical Research Manager
- Phone Number: 855-213-9890
- Email: BSNClinicalTrials@bsci.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Subject with PD implanted bilaterally in the STN and receiving DBS therapy for at least 3 months.
- Tolerates > 12 hours OFF medication and, per clinical judgment, be able to perform all study related procedures.
- Able to understand the study requirements and the treatment procedures and must provide written informed consent before any study-specific tests or procedures are performed.
Key Exclusion Criteria:
- Exhibits significant psychiatric problems, including unrelated clinically significant depression as determined by the investigator.
- A female who is pregnant, is breastfeeding, or is of childbearing potential and planning to get pregnant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: New Programming Paradigm
This arm will include patients receiving stimulation with a new programming paradigm
|
A new programming paradigm will be evaluated.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in Quality of Life using new programming paradigm: PDQ-39
Time Frame: up to 12 weeks
|
Change in Parkinson's Disease Questionnaire (PDQ-39) summary index and sub-scores
|
up to 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Natalie Bloom Lyons, Boston Scientific Neuromodulation Corporation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 13, 2019
Primary Completion (Estimated)
June 1, 2025
Study Completion (Estimated)
June 1, 2025
Study Registration Dates
First Submitted
October 30, 2018
First Submitted That Met QC Criteria
November 6, 2018
First Posted (Actual)
November 7, 2018
Study Record Updates
Last Update Posted (Actual)
June 12, 2024
Last Update Submitted That Met QC Criteria
June 11, 2024
Last Verified
June 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A4058
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease (PD)
-
University of FloridaCompletedParkinson Disease (PD)United States
-
Chang Gung UniversityCompleted
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
-
AbbVieCompletedParkinson's Disease (PD)United States, Australia
-
AbbVieRecruitingParkinson's Disease (PD)Germany, Denmark, Spain, Israel
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia, Belgium, Canada, Denmark, Germany, Italy, Japan, Netherlands, Russian Federation, Spain, United Kingdom, Sweden
-
Baylor College of MedicineCompletedIdiopathic Parkinson's Disease (PD)United States
-
AbbVieRecruiting
Clinical Trials on New Programming Paradigm
-
The Hong Kong Polytechnic UniversityUnknown
-
Universitaire Ziekenhuizen KU LeuvenRecruiting
-
Thomas KöglspergerUniversity Hospital Muenster; Heinrich-Heine University, Duesseldorf; Universitätsklinikum... and other collaboratorsRecruitingParkinson Disease | Telemedicine | Deep Brain StimulationGermany
-
Universitaire Ziekenhuizen KU LeuvenRecruiting
-
SGX Nova LLCCompletedChronic Back PainUnited States
-
University of Maryland, College ParkNational Institute on Aging (NIA)Recruiting
-
University Hospital, GhentResearch Foundation FlandersCompletedEpilepsyBelgium, United States
-
Cairo UniversityRecruitingSystemic Lupus ErythematosusEgypt
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingParkinson Disease | Deep Brain Stimulation | ImagingNetherlands
-
Vanderbilt University Medical CenterThoratec CorporationCompleted